These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23814163)

  • 1. Melanoma: more answers, more questions.
    Urba WJ
    Oncologist; 2013 Jun; 18(6):658-60. PubMed ID: 23814163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipilimumab and its toxicities: a multidisciplinary approach.
    Fecher LA; Agarwala SS; Hodi FS; Weber JS
    Oncologist; 2013 Jun; 18(6):733-43. PubMed ID: 23774827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma treatment's changing landscape.
    Jenks S
    J Natl Cancer Inst; 2014 Jun; 106(6):dju176. PubMed ID: 24907389
    [No Abstract]   [Full Text] [Related]  

  • 4. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
    Ascierto PA
    Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):811-26. PubMed ID: 27403706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of molecular alterations with immune response in melanoma.
    Szczepaniak Sloane RA; Gopalakrishnan V; Reddy SM; Zhang X; Reuben A; Wargo JA
    Cancer; 2017 Jun; 123(S11):2130-2142. PubMed ID: 28543700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Therapy Options for Patients With Unresectable Melanoma.
    Yushak M; Chapman P; Robert C; Kudchadkar R
    Am Soc Clin Oncol Educ Book; 2017; 37():661-672. PubMed ID: 28561662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
    Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
    Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.
    Smyth MJ; Yagita H; McArthur GA
    J Clin Oncol; 2016 Apr; 34(12):e104-6. PubMed ID: 25311221
    [No Abstract]   [Full Text] [Related]  

  • 10. Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.
    Aya F; Fernández-Martínez A; Gaba L; Victoria I; Tosca M; Carrera C; Prat A; Arance A
    Immunotherapy; 2016 Jun; 8(6):687-92. PubMed ID: 27115320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
    O'Regan KN; Jagannathan JP; Ramaiya N; Hodi FS
    AJR Am J Roentgenol; 2011 Aug; 197(2):W241-6. PubMed ID: 21785048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.
    Luke JJ; Hodi FS
    Oncologist; 2013 Jun; 18(6):717-25. PubMed ID: 23709751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapies for unresectable and metastatic melanoma.
    Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
    BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
    [No Abstract]   [Full Text] [Related]  

  • 14. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
    Day F; Kumar M; Fenton L; Gedye C
    J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Melanoma- finally good news].
    Wicki A; Arnold AW; Itin PH; Zippelius A
    Praxis (Bern 1994); 2013 May; 102(11):667-70. PubMed ID: 23692905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status.
    Gangadhar TC; Schuchter LM
    JAMA Oncol; 2015 Jul; 1(4):427-8. PubMed ID: 26181246
    [No Abstract]   [Full Text] [Related]  

  • 17. Cumulative dermatologic toxicity with ipilimumab and vemurafenib responsive to corticosteroids.
    Ludlow SP; Pasikhova Y
    Melanoma Res; 2013 Dec; 23(6):496-7. PubMed ID: 24025700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
    Yamazaki N; Maeda Y
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
    [No Abstract]   [Full Text] [Related]  

  • 19. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
    Alexander M; Mellor JD; McArthur G; Kee D
    Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonmalignant cutaneous findings associated with vemurafenib.
    Sukhnandan F; Kahn MR; Bhattacharjee P
    Cutis; 2018 Jan; 101(1):E2-E4. PubMed ID: 29529120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.